Strona główna・Stock List・Arcus Biosciences Inc

Arcus Biosciences Inc

Open

SectorHealthcare

22.52 0.18

Buy Sell

Overview

Share price change

24h

Current

Min

22.29

Max

23.38

Key metrics
By Trading Economics
Income	37M -91M
Sales	24M 41M
EPS	-0.72
Profit margin	-221.951
Employees	601
EBITDA	38M -85M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+72.45% upside

Dividends
By Acuity
Next Earnings	26 paź 2026

Market Stats
By TradingEconomics
Market Cap	-413M 3.1B
Previous open	22.34
Previous close	22.52

Arcus Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 paź 2026, 20:01 UTC

Arcus Biosciences Inc shares fell sharply, marking a departure from recent upward momentum and contrasting with higher daily closes in previous sessions.

8 paź 2026, 20:07 UTC

Arcus Biosciences Inc shares are declining, closing significantly lower since Wednesday and near the bottom of their one-month range after an earlier session pullback.

7 paź 2026, 19:46 UTC

Arcus Biosciences Inc shares are higher, having gained ground but remain below their 20-day moving average and near the lower end of their one-month range.

6 paź 2026, 20:30 UTC

Arcus Biosciences Inc's shares declined in after-market trading, currently at their lowest point of the day and well below the 20-day moving average.

5 paź 2026, 20:06 UTC

News

Arcus Biosciences Inc is advancing, supported by broader market movements, and has gained since Friday's close, despite earlier pulling back from a session high.

2 paź 2026, 20:02 UTC

Arcus Biosciences Inc shares fell sharply, reversing earlier gains, and remain below their 20-day moving average amid ongoing weakness.

1 paź 2026, 20:08 UTC

Correlated Moves

Nektar Therapeutics' disappointing Phase 2b study results contributed to a broader downturn in biotechnology, with the SPDR S&P Biotech ETF also lower.

30 wrz 2026, 20:07 UTC

News

Arcus Biosciences Inc shares are advancing modestly as Wedbush reiterates its Outperform rating and maintains a $43 price target.

29 wrz 2026, 20:07 UTC

Arcus Biosciences Inc is advancing, reflecting a notable increase since Monday's close, although it remains below its 20-day moving average.

28 wrz 2026, 19:15 UTC

Arcus Biosciences Inc is advancing, having reached a notable peak today, despite trading below its 20-day moving average and three prior sessions closing lower.

25 wrz 2026, 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

24 wrz 2026, 20:01 UTC

Arcus Biosciences Inc shares fell sharply, continuing a downward trend from Wednesday's close and trading well below its 20-day moving average.

23 wrz 2026, 20:07 UTC

Correlated Moves

Arcus Biosciences Inc shares fell amid a broader market downturn and rising U.S. Treasury yields, despite earlier reaching a session high.

22 wrz 2026, 20:06 UTC

Arcus Biosciences Inc is advancing amid a strong biotechnology sector, gaining ground since Monday's close but remains below its 20-day moving average.

21 wrz 2026, 19:16 UTC

Arcus Biosciences Inc is trading higher since Friday's close, despite being below its 20-day moving average and near the lower end of its one-month range.

18 wrz 2026, 20:13 UTC

Arcus Biosciences Inc is advancing in after-market trading following Friday's close, despite being positioned below its 20-day moving average.

17 wrz 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences is advancing, building on prior momentum, amid a broader biotech sector uptick driven by positive Phase 3 results from Moderna's cancer vaccine trial.

16 wrz 2026, 23:06 UTC

Arcus Biosciences Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

15 wrz 2026, 19:36 UTC

Correlated Moves

RCUS lower today, tracking declines in SPDR S&P Biotech ETF.

14 wrz 2026, 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 wrz 2026, 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 wrz 2026, 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 wrz 2026, 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 wrz 2026, 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 wrz 2026, 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 sie 2026, 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 sie 2026, 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 sie 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 sie 2026, 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 sie 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

Peer Comparison

Price change

Arcus Biosciences Inc Forecast

Price Target

By TipRanks

72.45% upside

12 Months Forecast

Average 38.818 USD 72.45%

High 47 USD

Low 23 USD

Based on 12 Wall Street analysts offering 12 month price targets forArcus Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Arcus Biosciences Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.